Antipsychotic drugs remain the foundation of schizophrenia treatment, and every approved option until very recently worked by dampening dopamine signaling in the brain. These medications fall into several generations, each with a distinct side-effect profile that often matters more to daily life than differences in symptom control. The landscape shifted in 2024 with the approval of the first non-dopamine-blocking antipsychotic, and several other novel approaches are in development, but for most people living with schizophrenia the core treatment decision still comes down to choosing among existing antipsychotics and figuring out how to manage their trade-offs.
Where Antipsychotic Drugs Came From
The story starts with chlorpromazine, a compound originally synthesized in the early 1950s as part of antihistamine research. Instead of a better allergy drug, researchers got a medication that transformed the treatment of psychosis and kicked off what has been called the “psychopharmacological revolution.”1PubMed. History of the discovery and clinical introduction of chlorpromazine Chlorpromazine and the drugs that followed it, now called first-generation or “typical” antipsychotics, work primarily by blocking dopamine D2 receptors in the brain.2PubMed Central. History of the dopamine hypothesis of antipsychotic action This mechanism is effective at tamping down hallucinations, delusions, and disorganized thinking. It also explains a major limitation: roughly a third of people with schizophrenia do not respond adequately to dopamine-targeting drugs.3Frontiers in Psychiatry (via Europe PMC). Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
First-Generation Versus Second-Generation Antipsychotics
First-generation antipsychotics like haloperidol and chlorpromazine are still used worldwide, but they come with a well-known problem: movement-related side effects, collectively called extrapyramidal symptoms. These include muscle stiffness resembling Parkinson’s disease, a distressing inner restlessness called akathisia, and involuntary repetitive movements known as tardive dyskinesia. A meta-analysis pooling data from observational studies found that roughly 30 to 37 percent of people taking antipsychotics experience some form of these movement side effects, with drug-induced parkinsonism being the most common at about 20 percent, akathisia at about 11 percent, and tardive dyskinesia at about 7 percent.4PLOS ONE. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
Second-generation or “atypical” antipsychotics, introduced starting in the 1990s, were designed partly to avoid these movement problems. They work by blocking serotonin 2A receptors in addition to dopamine D2 receptors, and they also stimulate serotonin 1A receptors directly or indirectly.5Current Opinion in Pharmacology. The role of serotonin receptors in the action of atypical antipsychotic drugs This different receptor profile does reduce the risk of extrapyramidal symptoms, but it introduced a new set of concerns: weight gain, high blood sugar, unhealthy cholesterol levels, and elevated blood pressure, all components of metabolic syndrome.6PubMed Central. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences Not all second-generation drugs carry the same metabolic risk. Olanzapine and clozapine are at the top of the list for weight gain, while drugs like aripiprazole and ziprasidone tend to cause less.7PubMed Central. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
So in practice, the choice between generations is not “better versus worse” but “which set of side effects is more manageable for this person.” Someone with a family history of diabetes might steer away from olanzapine. Someone especially sensitive to movement side effects might avoid older first-generation drugs. This trade-off shapes nearly every prescribing decision.
How Antipsychotics Actually Compare
A landmark network meta-analysis compared 32 oral antipsychotics for acute treatment of multi-episode schizophrenia by synthesizing hundreds of randomized trials involving tens of thousands of participants. The headline finding: most antipsychotics reduced overall symptoms more than a placebo, but differences between the drugs in terms of raw effectiveness were surprisingly small. Only clozapine, amisulpride, olanzapine, risperidone, and zotepine stood out as clearly more effective than many of the others.8PubMed Central. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis The same analysis confirmed what clinicians have long observed: antipsychotics differ more in their side effects than in how well they control symptoms.9The Lancet. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with schizophrenia: a systematic review and network meta-analysis
This is a crucial point for anyone navigating treatment. If your doctor suggests switching from one antipsychotic to another, it is usually because the side effects are a problem, not because the new drug is dramatically more powerful at reducing psychosis. Finding the right medication often means finding the one whose side-effect profile you can live with.
Clozapine and Treatment-Resistant Schizophrenia
When two or more antipsychotics tried at adequate doses and durations fail to control symptoms, the diagnosis shifts to treatment-resistant schizophrenia. This applies to a substantial minority of patients. Clozapine is the only drug with strong evidence of superiority in this population. A large quantitative meta-review found that clozapine has superior effects on positive symptoms, negative symptoms, overall symptom burden, and relapse rates compared to both first-generation antipsychotics and pooled groups of other antipsychotics in treatment-resistant patients.10PubMed Central. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Despite that efficacy, clozapine is underused. The reason is a rare but serious side effect: it can cause a dangerous drop in white blood cells called agranulocytosis, which leaves the body vulnerable to life-threatening infections. People taking clozapine must have regular blood draws to monitor their white blood cell count, typically weekly at first and less frequently once stable. Clozapine also carries metabolic and cardiovascular risks that demand ongoing monitoring. But for someone who has not responded to other medications, the risk-benefit calculation generally favors it, provided that monitoring is in place.
Third-Generation Antipsychotics
Aripiprazole, approved in the early 2000s, is often called the first third-generation antipsychotic because it works differently from both older groups. Rather than simply blocking dopamine D2 receptors, it acts as a partial agonist, meaning it can turn D2 signaling partly up or partly down depending on how much dopamine is already present. Though the exact mechanism is debated, this approach appears to reduce the risk of both the movement side effects of first-generation drugs and the heavy metabolic load of some second-generation drugs.11PubMed Central. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
Several newer drugs now share this partial-agonist approach. Brexpiprazole, cariprazine, and lumateperone are all dopamine D2 partial agonists with varying receptor profiles.12International Clinical Psychopharmacology. Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences Cariprazine, for instance, has shown particular promise for negative symptoms, the motivational and social deficits of schizophrenia that older drugs barely touch. These third-generation options are increasingly prescribed as first-line treatments because of their relatively favorable side-effect profiles, though they are not necessarily more effective at controlling hallucinations and delusions than older drugs.
The First Drug That Skips Dopamine Entirely
Every approved antipsychotic prior to 2024 worked at least partly by blocking or modulating dopamine D2 receptors. Xanomeline-trospium, marketed as KarXT and approved by the FDA in late 2024, broke that pattern. It works through muscarinic receptors instead, specifically by activating M1 and M4 subtypes in the brain.13The Lancet. Efficacy and safety of xanomeline–trospium chloride in schizophrenia, the EMERGENT-2 study This matters because dopamine blockade is responsible for many of the side effects people dislike most, from movement problems to hormonal changes like elevated prolactin. A drug that bypasses dopamine receptors could potentially avoid those issues.
The EMERGENT-2 trial found that KarXT significantly reduced both positive and negative symptoms of schizophrenia compared to a placebo, with a mean reduction in overall symptom scores roughly twice as large as the placebo group’s improvement.14The Lancet. Efficacy and safety of xanomeline–trospium chloride in schizophrenia, the EMERGENT-2 study The trospium component of the combination serves a clever purpose: xanomeline activates muscarinic receptors throughout the body, not just the brain, causing gastrointestinal side effects like nausea. Trospium blocks muscarinic receptors in the body but cannot cross into the brain, so it reduces those peripheral side effects without undoing xanomeline’s therapeutic work.15PubMed. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment It is still early days, and long-term data are limited, but the approval represents the first genuinely new mechanism in schizophrenia treatment in decades.
Long-Acting Injectables
One of the biggest obstacles in schizophrenia treatment is not finding a drug that works but getting people to take it consistently. Missing doses is common, and even brief gaps can trigger relapse. Long-acting injectable antipsychotics address this by delivering medication through an injection given every two weeks to every six months, depending on the formulation, rather than requiring a daily pill.
The clinical impact is substantial. A large adjusted analysis found that switching from oral to long-acting injectable antipsychotics was associated with a roughly 48 percent reduction in psychiatric hospitalizations and a 44 percent reduction in suicide attempts.16JAMA Network Open. Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia A three-year mirror-image study, where each patient served as their own comparison before and after the switch, found that average hospitalization days plummeted from about 10 days to near zero and relapses dropped by roughly 40 percent.17PubMed Central. Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study These improvements come largely from solving the adherence problem rather than from the injectable drug being inherently more potent than its oral version.18PubMed Central. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
Despite these benefits, long-acting injectables are still prescribed less often than the evidence would suggest. Some clinicians reserve them for patients who have already shown poor adherence, rather than offering them proactively. Some patients dislike injections or feel that the format removes a sense of control over their own treatment. These are real concerns, and the decision should be a shared one.
Why Stopping Medication Is Risky
A persistent question for people who feel stable on antipsychotics is whether they can taper off. The evidence is not encouraging. A systematic review and network meta-analysis of studies comparing continuation, dose reduction, switching, and stopping found that all continuation strategies were far better at preventing relapse than discontinuation. Staying on a standard dose reduced relapse risk by about 63 percent compared to stopping, and even a dose reduction roughly halved the risk of relapse relative to stopping entirely.19PubMed. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable
This does not mean nobody can ever reduce their dose. It means that any tapering attempt should be slow, closely monitored, and guided by a clinician, and that most people with a confirmed diagnosis of schizophrenia will need some level of ongoing medication to stay well.
The Gap in Treating Negative and Cognitive Symptoms
Antipsychotics are reasonably good at controlling “positive” symptoms like hallucinations and delusions. They are much less effective at treating “negative” symptoms: flattened emotional expression, low motivation, social withdrawal, reduced speech, and difficulty experiencing pleasure. These negative symptoms are actually the main driver of long-term functional disability in schizophrenia, affecting the ability to hold a job, maintain relationships, and live independently.20PubMed. Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
No single drug is proven as a definitive treatment for negative symptoms. The best available evidence supports off-label trials of cariprazine, olanzapine, clozapine, and amisulpride as single agents, or adding medications like memantine, ondansetron, minocycline, or antidepressants alongside an antipsychotic.21PubMed. Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape Cognitive problems, including difficulties with memory, attention, and planning, are another major unmet need. The glutamate system, particularly a receptor called NMDA, has been a prime research target for cognitive and negative symptoms, since these are the domains that dopamine-focused drugs largely miss.22PubMed Central. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment Unfortunately, drugs designed to boost NMDA receptor function have mostly failed in clinical trials so far.23Translational Psychiatry. Glutamatergic dysfunction in Schizophrenia The search continues, and glutamate modulation remains a promising but unproven frontier.24PubMed Central. Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine
Medication Choices for a First Psychotic Episode
People experiencing psychosis for the first time tend to respond to lower doses of antipsychotics than those who have had multiple episodes.25PubMed. Pharmacotherapy of first-episode psychosis They are also more sensitive to side effects, which makes the initial drug selection especially important. Current practice generally favors starting with a second- or third-generation antipsychotic at a low dose and titrating up gradually. When older first-generation drugs like haloperidol are used, even low doses have been shown to cause worse movement side effects compared to newer options.26PubMed. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons
The stakes of getting early treatment right are high. A bad experience with side effects at the start can shape a person’s willingness to take medication for years afterward. This is one reason many guidelines now emphasize shared decision-making and careful monitoring during the first episode.
Why Medication Alone Is Not Enough
Antipsychotics address the biological component of schizophrenia, but adding psychosocial interventions dramatically improves outcomes. A randomized trial of early-stage schizophrenia found that combining medication with psychosocial treatment (including psychoeducation, family intervention, and skills training) reduced the risk of relapse by about 43 percent and the risk of treatment discontinuation by about 38 percent compared to medication alone. People in the combined group also showed greater improvements in social functioning, daily living skills, and quality of life, and a significantly higher proportion found employment or returned to education.27PubMed Central. Antipsychotic Medication Alone versus Combined with Psychosocial Intervention on Outcomes of Early Stage Schizophrenia: A Randomized, One-year Study
Social skills training specifically has shown impressive effects on functional recovery. In one study, over 90 percent of patients receiving social skills training alongside their medication met criteria for symptom remission, compared with about two-thirds in the medication-only group. When the bar was raised to include both symptom remission and meaningful functional improvement, virtually all of those who achieved it were in the combined-treatment group.28PubMed. The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia The message here is that drugs can suppress symptoms, but recovering a functional life typically requires rehabilitation, therapy, and social support working alongside medication.
Pharmacogenomics and Personalized Prescribing
One of the frustrations of schizophrenia treatment is trial and error. A drug that works well for one person may be ineffective or intolerable for another, and there is no reliable way to predict who will respond to what. Pharmacogenomic testing, which looks at genetic variations that influence how a person metabolizes or responds to a drug, is an active area of research aimed at shortening that guessing game.29PubMed Central. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside
The idea is appealing: a simple genetic test before prescribing could flag which drugs are likely to cause severe side effects or which doses need adjustment. Case reports have already shown this working in individual patients, where genetic testing explained why someone reacted badly to one antipsychotic and guided a successful switch to another.30PubMed Central. Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics For clozapine in particular, identifying genetic markers that predict who will tolerate it and who will not could help more treatment-resistant patients gain access to the most effective drug available.31PubMed Central. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics In practice, though, widespread routine genetic testing before prescribing antipsychotics is not yet standard. The research identifies promising markers, but translating those into decision tools that reliably change outcomes across large populations is still a work in progress.
Antipsychotics During Pregnancy
Pregnancy creates a genuine dilemma for women with schizophrenia. Stopping antipsychotic medication raises the risk of symptom relapse considerably: one analysis found a 53 percent risk of worsening over 10 months after discontinuation, compared to a 16 percent relapse rate among those who continued treatment.32PubMed Central. Use of Antipsychotic Drugs During Pregnancy Psychotic relapse during pregnancy carries its own serious risks for both mother and baby, including poor prenatal care, self-harm, and preterm delivery.
At the same time, antipsychotics cross the placenta, and data on long-term effects on fetal development remain limited for most individual drugs. The general clinical approach is to use the lowest effective dose of a medication with the most safety data in pregnancy, weighed against the very real dangers of untreated psychosis. This is a decision that requires close collaboration between the patient, a psychiatrist, and an obstetrician, ideally starting before conception when planning is possible.
The Role of Subjective Experience in Sticking With Treatment
Adherence remains one of the central challenges of schizophrenia pharmacotherapy. People stop taking their medication for many reasons: feeling better and believing they no longer need it, lack of insight into their illness, cognitive difficulties that make remembering doses hard, and side effects that feel worse than the symptoms they are meant to treat. Research into the subjective experience of side effects has highlighted that the burden is complex and varies by age and gender, and that specific side effects correlate with specific patterns of missed doses.33Academia.edu / Journal of Advanced Nursing. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia Weight gain, sedation, and sexual dysfunction are among the most commonly cited reasons people give for wanting to stop.
This is why shared decision-making has gained traction in psychiatry. When patients have a voice in choosing which drug to try, understand the trade-offs, and feel that their complaints about side effects are taken seriously, they are more likely to stay engaged with treatment. Clinicians who dismiss side-effect complaints or frame adherence purely as a compliance problem miss the point. The medication that a person actually takes consistently is better than a theoretically superior drug that sits in a drawer.